Mesa Labs Q1 revenue rises as calibration, biopharma units grow

Mesa Laboratories

10/08/2026 21:12

Overview
US life science tools maker's fiscal Q1 revenue rose 1.0% year-over-year
Adjusted operating income excluding unusual items increased 19.5%
Net income fell 40.3% due to higher nonoperating expense

Outlook
Mesa Laboratories plans to provide full-year guidance in November with first-half results

Result Drivers
DIVISIONAL PERFORMANCE - Revenue growth was driven by Calibration Solutions and Biopharmaceutical Development divisions, while Sterilization and Disinfection Control declined due to fulfillment and delivery execution challenges; Clinical Genomics was flat with ongoing weakness in China
GROSS MARGIN VARIATION - Gross profit margin rose in BPD, CS, and CG due to favorable product mix, supply chain efficiencies, and higher revenues on a partially fixed cost base, but declined in SDC due to lower revenues and product mix
INVESTMENT IN SDC - Company increased investment in Sterilization and Disinfection Control to support future organic growth

Company press release: ID:nGNX8wSxTG

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
 
$0.49
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Mesa Laboratories, Inc. is $112.00, about 9.1% above its August 7 closing price of $102.65
The stock recently traded at 56 times the next 12-month earnings vs. a P/E of 71 three months ago

Reuters Recommended Reads
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Aug 10 - Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boost
Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)